



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Patent Application of Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
Serial No. 09/613,038	Docket No.: 22338-602
Filed: July 10, 2000	Group Art Unit: 1636
For: BLOCKING IMMUNE RESPONSE TO A GRAFT (Amended)	

Box Patent Application  
Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

1. ☒ The Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of an Office Action.
  - a) ☒ Attached is our check in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449 documents, and to indicate in the official file wrapper of this patent application that these documents have been considered.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Sharon E. Stroup", written over the typed name.

Sharon E. Stroup  
Reg. No. 32,056  
Attorney for Applicant

SIDLEY AUSTIN BROWN & WOOD LLP  
1501 K Street, N.W.  
Washington, D.C. 20005  
(202) 736-8000

Dated: November 5, 2003

SES/yea  
Enclosures



CHICAGO  
DALLAS  
LOS ANGELES  
NEW YORK  
SAN FRANCISCO

# SIDLEY AUSTIN BROWN & WOOD LLP

1501 K STREET, N.W.  
WASHINGTON, D.C. 20005  
TELEPHONE 202 736 8000  
FACSIMILE 202 736 8711  
www.sidley.com  
FOUNDED 1866

BEIJING  
GENEVA  
HONG KONG  
LONDON  
SHANGHAI  
SINGAPORE  
TOKYO

WRITER'S DIRECT NUMBER  
(202) 736-8914

WRITER'S E-MAIL ADDRESS  
jkushan@sidley.com

November 5, 2003

## VIA HAND CARRY

Examiner Quang Nguyen  
U.S. Patent and Trademark Office  
Group Art Unit 1636  
Washington, DC 20231


Re: U.S. Patent Application No. 09/613,038  
For: TREATMENT OF AUTOIMMUNIE DISEASES  
Docket No.: 22338-602

Dear Examiner Nguyen:

Pursuant to your request in the Office Action dated March 3, 2003, attached please find the missing references cited in the above-identified patent application and a copy of the PTO-1449 to which the missing references pertain.

Please do not hesitate to contact me if you should have any further questions regarding this matter.

Very truly yours,



Jeffrey P. Kushan

JPK:yea

Enclosures

PTO-1449

NOV 05 2003

U.S. Dept. of Commerce  
Patent and Trademark Office

App Docket No.

P1752R1

Serial No.

09/613,038

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

## LIST OF DISCLOSURES GIVEN BY APPLICANT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
QN	1	4,975,278	04.12.90	Senter, P. et al.	424	178.1	
	2	5,417,972	23.05.95	Bhat, N. M. et al.	424	137.1	
	3	5,540,926	30.07.96	Aruffo, A. et al.	424	153.1	
	4	5,587,459	24.12.96	Uckun	530	391.1	
	5	5,593,676	14.01.97	Bhat, N. M. et al.	424	137.1	
	6	5,595,721	21.01.97	Kaminski et al.	424	1.49	
	7	5,677,180	14.10.97	Robinson et al.	435	328	
	8	5,686,072	11.11.97	Uhr et al.	424	18.1	
	9	5,693,780	02.12.97	Newman, R. A. et al.	536	23.53	
	10	5,721,108	24.02.98	Robinson et al.	435	7.23	
	11	5,736,137	07.04.98	Anderson et al.	424	133.1	
	12	5,786,456	28.07.98	Ledbetter, J. A. et al.	530	388.73	
	13	5,795,569	18.08.98	Bartley et al.	424	85.1	
	14	5,872,223	16.02.99	Uckun	530	391.1	
	15	5,877,299	02.03.99	Thomas et al.	530	413	


## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No	
	16	405,972 A1 ✓	02.01.91	EPO				
	17	540,859 B1 ✓	14.01.98	EPO				
	18	585,943 B1 ✓	11.02.98	EPO				
	19	701,130 A2 ✓	13.03.96	EPO				
	20	WO 00/06694 ✓	10.02.00	PCT				
	21	WO 00/09160 ✓	24.02.00	PCT				
	22	WO 00/27428 ✓	18.05.00	PCT				
	23	WO 00/27433 ✓	18.05.00	PCT				
	24	WO 91/13974 ✓	19.09.91	PCT				
	25	WO 93/25673 ✓	23.12.93	PCT				
	26	WO 95/03770 ✓	09.02.95	PCT				
	27	WO 95/14230 ✓	26.05.95	PCT				
	28	WO 97/13529 ✓	17.04.97	PCT				
	29	WO 97/31025 ✓	28.08.97	PCT				
	30	WO 97/34633 ✓	25.09.97	PCT				
	31	WO 98/04281 ✓	05.02.98	PCT				
	32	WO 98/16254 ✓	23.04.98	PCT				
	33	WO 99/30738 ✓	24.06.99	PCT				

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT</b> 	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	
	Filing Date: July 10, 2000	Examiner: Quang Nguyen
		Group Art Unit: 1636

### FOREIGN PATENT DOCUMENTS (CONTINUED)

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
154	WO 98/56418 A1	12/17/1998	PCT				
155	EP 0 330 191 B1	10/02/1996	Europe				
156	WO 0042072 A3	07/20/2000	PCT				
157	WO 00/20864 A1	04/13/2000	PCT				
158	WO 99/51642 A1	10/14/1999	PCT				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

159	Eisenberg, R. "Anti B-Cell Therapy in the Treatment of Autoimmune Disease." Genentech Oncology and IDEC Pharmaceuticals Investigator-Sponsored Protocol Concept Worksheet.
160	Gryn, J. Clinical Research Proposal.
161	Latov, N. "Rituxan for Treatment of Neuropathy and IgM Monoclonal Gammopathy with Anti-MAG or Sulfatide Antibody Activity." New Clinical Study Application.
162	Looney, R.J. Clinical Research Proposal.
163	Pestronk, A. "A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies." Clinical Research Proposal.
164	Saleh et al. "A Phase II Study of Rituxan in the Treatment of Immune Thrombocytopenic Purpura." Clinical Research Proposal.
165	Friend et al. "Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection." Transplantation, Vol. 68, 1999, pp. 1625-1631.
166	Edwards, J.C.W. et al. "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes." Rheumatology, Vol. 40, 2001, pp. 205-211.
167	Edwards, J.C.W. et al. "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders." Biochemical Society Transactions, Vol. 30, part 4, 2002, pp. 824-828.
168	Eisenberg, Robert A. Genentech Investigator-Sponsored Protocol Concept Worksheet
169	Leandro, M.J. et al. "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion." Ann Rheum Dis, Vol. 61, 2002, pp. 883-888.
170	Leandro, M.J. et al. "An Open Study of B Lymphocyte Depletion in Systemic Lupus Erythematosus." Arthritis & Rheumatism, Vol. 46, No. 10, October 2002, pp. 2673-2677.
171	Matthews, Robert. "Medical Heretics." New Scientist, April 7, 2001, pp. 34-37.
172	Stasi, R. et al. "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura." Blood, Vol. 98, No. 4, August 2001, pp. 952-957.
173	Juan M. Arnada et al.; Anti-CD20 Monoclonal Antibody (Rituximab) Therapy for Acute Cardiac Humoral Rejection: A Case Report; Transplantation, 2000, pp. 907-910
174	Voravit Ratanatharathorn et al. "Anti-CD20 Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease", Annals of Internal Medicine, August 2000, pp. 275-279
175	C. Anasetti et al. "Graft-v-Host Disease is Associated with Autoimmune-like Thrombocytopenia", The Journal of The American Society of Hematology, Vol. 73, No. 4, March 1989, pp. 1054-1058

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Form PTO-A820 (also form PTO-1449)**

**SHEET 2 OF 2**

<b>INFORMATION DISCLOSURE STATEMENT</b> P E J C I 7 A 0 5 2003 TRADEMARK OFFICE	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
	Filing Date: July 10, 2000	Group Art Unit: 1636

### U.S. PATENT DOCUMENTS

Examiner (Initial)	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	119	60/105,014	10/20/1998	Raubitschek et al.			
	120	2003/0026801 A1	02/06/2003	Weiner et al.			
	121	2003/0021781 A1	01/30/2003	Anderson et al.			
	122	2002/0197256 A1	12/26/2002	Grewal			
	123	2002/0197255 A1	12/26/200	Anderson et al.			
	124	2002/0128488 A1	09/12/2002	Yamakawa et al.			
	125	2002/0004587 A1	01/10/2002	Miller et al.			
	126	6,528,624 B1	03/04/2003	Idusogie et al.			
	127	6,410,391 B1	06/25/2002	Zelsacher			
	128	6,368,596 B1	04/09/2002	Ghetie et al.			
	129	6,287,537 B1	09/11/2001	Kaminski et al.			
	130	6,242,195 B1	06/05/2001	Idusogie et al.			
	131	6,224,866 B1	05/01/2001	Barbera-Guillem			
	132	6,194,551 B1	02/27/2001	Idusogie et al.			
	133	6,171,586 B1	01/09/2001	Lam et al.			
	134	6,090,365	07/18/2000	Kaminsky et al.			
	135	6,015,542	01/18/2000	Kaminsky et al.			
	136	5,849,898	12/15/1998	Seed et al.			
	137	5,843,439	12/01/1998	Anderson et al.			
	138	5,843,398	12/01/1998	Kaminsky et al.			
	139	4,861,579	08/29/1989	Meyer, Jr. et al.			
	140	2003/0133930 A1	7/17/2003	Goldenberg et al.			

### FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
141	WO 02/102312 A2	12/27/2002	PCT				
142	WO 02/096948 A2	12/05/2002	PCT				
143	WO 02/079255 A1	10/10/2002	PCT				
144	WO 02/04021 A1	01/17/2002	PCT				
145	WO 01/80884 A1	11/01/2001	PCT				
146	WO 01/77342 A1	10/18/2001	PCT				
147	WO 01/74388 A1	10/11/2001	PCT				
148	WO 01/10461 A1	02/15/2001	PCT				
149	WO 00/72333 A1	11/30/2000	PCT				
150	WO 00/67795 A1	11/16/2000	PCT				
151	WO 00/44788 A1	08/03/2000	PCT				
152	WO 99/22764 A1	05/14/1999	PCT				
153	WO 98/58964 A1	12/30/1998	PCT				

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 2

PTO-1449

NOV 05 2003

U.S. Dept. of Commerce  
Patent and Trademark Office

Docket No.

P1752R1

Serial No.

09/613,038

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

		"Amgen Discontinues Development of MAb" (press release) (September 11, 1998)
	34	
	35	Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation" <u>Blood</u> 63(6):1424-1433 (1984)
QN	36	Ballester et al., "Rituximab can be safely included as part of high-dose therapy/autologous stem cell transplantation for patients with Non-Hodgkin's lymphoma" <u>Blood</u> (Abstract #4552) 92(10 Suppl. 1 part 1-2):360b-361b (Nov 15, 1998)
	37	Bellon et al., "Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial" <u>Human Gene Therapy</u> 8:15-25 (1997)
QN	38	Buckstein et al., "The effects of in vivo purging with Rituxan on stem cell mobilization efficacy, harvest purity, cytokine profile and engraftment in patients with relapsed follicular lymphoma undergoing autologous stem cell transplant" <u>Blood</u> (Abstract #2672) 92(10 Suppl. 1 Part 1-2):647a (1998)
	39	Bussell, J.B., "Autoimmune Thrombocytopenic Purpura" <u>Hematology - Oncology Clinics of North America</u> 4(1):179-191 (Feb 1990)
	40	Christ et al., "Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response" <u>Immunology Letters</u> 57:19-25 (1997)
QN	41	Cook et al., "Effective Treatment of Lymphoproliferative Disease following Lung Transplantation using Monoclonal Anti-CD20 B-Cell Antibody" <u>The Journal of Heart and Lung Transplantation</u> (abstract only) 18:84-85 (January 1999)
	42	Demidem et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs" <u>Cancer Biotherapy &amp; Radiopharmaceuticals</u> 12(3):177-186 (1997)
	43	Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains" <u>EMBO Journal</u> 7(3):711-717 (1988)
QN	44	Faye et al., "Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders" <u>Lancet</u> 352:1285 (Oct 17, 1998)
QN	45	Flinn et al., "In vivo purging and adjuvant immunotherapy with Rituximab during PBSC transplant for NHL" <u>Blood</u> (Abstract #2673) 92(10 Suppl 2 part 1-2):648a (Nov 15, 1998)
	46	George et al., "Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology" <u>Blood</u> 88(1):3-40 (Jul 1, 1996)
QN	47	John et al., "Anti-CD20 monoclonal antibody for the treatment of post-transplant lymphoproliferative disease in a pediatric heart transplant recipient." <u>Journal of Investigative Medicine</u> 4(2):125A (Feb 1999)
	48	Johnston, "Rituximab-Associated Immune Thrombocytopenic Purpura" <u>Blood</u> 94(10):4386 (1999)
	49	Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytotoxicity" <u>Leukemia Research</u> 11(12):1119-1125 (1987)
	50	Knoell, "Clinical Aspects of Gene Therapy" <u>The Annals of Pharmacotherapy</u> 32:977-979 (September 1998)
	51	Korholz et al., "Humoral immunodeficiency in patients after bone marrow transplantation" <u>Bone Marrow Transplantation</u> 18:1123-1130 (1996)
QN	52	Lee et al., "Rituxan in the treatment of cold agglutinin disease" <u>Blood</u> 92(9):3490-3491 (Nov 1, 1998)

Examiner

Date Considered

02/01/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.

**LIST OF DISCLOSURES CITED BY APPLICANT**  
(Use several sheets if necessary)

U.S. Dept. of Commerce  
Patent and Trademark Office

Docket No.

P1752R1

Serial No.

09/613,038

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

QN	53	Levine et al., "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab" <u>Neurology</u> 52:1701-1704 (May 12, 1999)
	54	Maloney et al., "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (nhl) cell lines" <u>Blood</u> (Abstract #2535) 88(10):637a (1996)
QN	55	Mow et al., "Rituximab for the Treatment of Refractory Immune Thrombocytopenic Purpura - Case Report" <u>Blood</u> 94:3526 (1999)
	56	Nadler et al., "B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes" <u>J. Immunol.</u> 131(1):244-250 (Jul 1983)
	57	Nadler et al., "Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies" <u>Progress in Hematology</u> , Brown, E., Grune & Stratton, Inc. Vol. XII:187-225 (1981)
	58	Nadler, L. <u>Lymphocyte Typing II</u> , Renling et al., Springer Verlag Vol. 2:3-37 and Appendix (1986)
	59	Notoya et al., "Chronic cold agglutinin disease accompanied with an increase of CD20 <sup>+</sup> /CD5 <sup>+</sup> cells; a case report" <u>The Japanese Journal of Clinical Hematology</u> (English language abstract of attached Japanese article) 35(9):881-885 (Sep 1994)
	60	Ooto et al., "Quantitative Flowcytometric Analysis of B Cell Surface Antigens in Patients with Autoimmune Diseases" <u>The Japanese Journal of Clinical Pathology</u> (English language abstract of attached Japanese article) 43(4):381-384 (Apr 1995)
	61	Pai-Scherf et al., "A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab" (Clinical Research Proposal)
	62	Paulus et al., "Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo" <u>Athrititis Rheum.</u> 33(4):477-484 (Apr 1990)
	63	Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to Rituximab" <u>Blood</u> (Abstract #3360) 92 (Nov 1998)
	64	Pescovitz, "Pilot Study of Rituxin (anti-CD20) for the reduction of high titered anti-HLA antibodies in patients with renal failure awaiting renal transplant." (Clinical Trial Proposal)
	65	Pescovitz, "Pilot study of Rituxin (anti-CD20) for the reduction of high titered anti-HLA antibodies in patients with renal failure awaiting renal transplant." (Letter to Dr. Grillo-Lopez and Protocol Concept Sheet)
	66	Piasecik, P., "New therapeutic monoclonal antibodies target kidney transplant rejection and cancer" <u>Journal of the American Pharmaceutical Association</u> 38(3):379-380 (May/Jun 1998)
QN	67	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" <u>Blood</u> 83(2):435-445 (Jan 15, 1994)
	68	Shan et al., "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies" <u>Blood</u> 91(5):1644-1652 (Mar 1, 1998)
	69	Sollinger (Letter to Dr. Bonni S. Dutcher) (December 23, 1998)
	70	Sollinger, "Phase 2 trial using Rituxin to desensitize patients awaiting renal transplant" (Investigator Initiated Protocol Concept Worksheet)
	71	Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation" <u>The Journal of Immunology</u> 135(2):973-979 (1985)
	72	Tedder et al., "The CD20 surface molecule of B lymphocytes functions as a calcium channel" <u>J. Cell. Biochem.</u> (Abstract # M 023) 14D:195 (1990)

Examiner

Date Considered

02/01/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

NOV 05 2003

U.S. Dept. of Commerce  
Patent and Trademark Office

Docket No.

P1752R1

Serial No.

09/613,038

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

- |    |  |
|----|--|
| 73 | Valle et al., "Bowel Permeability and CD45RO Expression on Circulating CD20+ B Cells in Patients with Ankylosing Spondylitis and Their Relatives" <u>The Journal of Rheumatology</u> 26(1):128-135 (1999)  |
| 74 | Valentine et al., "Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes" <u>Journal of Biological Chemistry</u> 264(19):11282-11287 (Jul 5, 1989)   |
| 75 | Vassilev et al., "Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)" <u>Clin. Exp. Immunol.</u> 92:369-372 (Feb 25, 1993)   |
| 76 | Watson et al., "A case of germinal center formation by CD45RO T and CD20 B lymphocytes in rheumatoid arthritic subchondral bone: proposal for a two-compartment model of immune-mediated disease with implications for immunotherapeutic strategies" <u>Clinical Immunology and Immunopathology</u> 73(1):27-37 (1994) |
| 77 | Wilkes et al., "Preferential production of IgG2 antibodies by parenchymal lung B-lymphocytes during lung allograft rejection" <u>Transplantation Proceedings</u> 29:1891-1895 (1997)   |
| 78 | Yokose et al., "Low-grade B cell lymphoma of mucosa-associated lymphoid tissue in the thymus of a patient with rheumatoid arthritis" <u>Pathology International</u> 48:74-81 (1998)  |
| 79 | Yu and Lennon, "Mechanism of Intravenous immune globulin therapy in antibody-mediated autoimmune diseases" <u>New England J. of Medicine</u> 340(3):227-228 (Jan 21, 1999)   |

Examiner

*Quay Nguyen*

Date Considered

02/01/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.